Efficient Clearance of Aspergillus fumigatus in Murine Lungs by an Ultrashort Antimicrobial Lipopeptide, Palmitoyl-Lys-Ala- d Ala-Lys
- 1 September 2008
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (9) , 3118-3126
- https://doi.org/10.1128/aac.00526-08
Abstract
Aspergillus fumigatus is an opportunistic fungal pathogen responsible for invasive aspergillosis in immunocompromised individuals. The inefficiency of antifungal agents and high mortality rate resulting from invasive aspergillosis remain major clinical concerns. Recently, we reported on a new family of ultrashort cationic lipopeptides active in vitro against fungi. Mode of action studies supported a membranolytic or a detergent-like effect. Here, we screened several lipopeptides in vitro for their anti-A. fumigatus activity. To investigate the therapeutic properties of the selected peptides in vivo, we challenged immunosuppressed C57BL/6 wild-type mice intranasally with DsRed-labeled A. fumigatus conidia and subsequently treated the animals locally with the lipopeptides. Confocal microscopic analysis revealed the degradation of DsRed-labeled hyphal forms and residual conidia in the lungs of the mice. The most efficient peptide was tested further using a survival assay and was found to significantly prolong the life of the treated animals, whereas no mice survived with the current standard antifungal treatment with amphotericin B. Moreover, as opposed to the drug-treated lungs, the peptide-treated lungs did not display any toxicity of the peptide. Our results highlight the potential of this family of lipopeptides for the treatment of pulmonary invasive aspergillosis.Keywords
This publication has 37 references indexed in Scilit:
- Ultrashort antibacterial and antifungal lipopeptidesProceedings of the National Academy of Sciences, 2006
- Antifungal Prophylaxis Is Effective against Murine Invasive Pulmonary AspergillosisAntimicrobial Agents and Chemotherapy, 2006
- Comparative Efficacies, Toxicities, and Tissue Concentrations of Amphotericin B Lipid Formulations in a Murine Pulmonary Aspergillosis ModelAntimicrobial Agents and Chemotherapy, 2006
- Weekly Paclitaxel Combined with Local Hyperthermia in the Therapy of Breast Cancer Locally Recurrent after Mastectomy – a Pilot ExperienceOncology Research and Treatment, 2004
- A Double‐Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised PatientsClinical Infectious Diseases, 2002
- Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected withAspergillusSpecies and Other Filamentous Fungi: Maximum Tolerated Dose StudyAntimicrobial Agents and Chemotherapy, 2001
- Intravenous Itraconazole Followed by Oral Itraconazole in the Treatment of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies, Chronic Granulomatous Disease, or AIDSClinical Infectious Diseases, 2001
- Diagnosis of Atypical Cases of Infectious MononucleosisClinical Infectious Diseases, 2001
- Clinical Significance of Nephrotoxicity in Patients Treated with Amphotericin B for Suspected or Proven AspergillosisClinical Infectious Diseases, 1999
- Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997